(Total Views: 387)
Posted On: 03/15/2018 6:00:50 PM
Post# of 72440
Now, allow me to preface by saying I think TIAB is not a Doctor, is a fudster, and I don't agree for the most part with his views on B-OM and Prurisol. On the matter of Kevetrin though:
Because the company has done this before. Allow me to share a few snippets from the PR that first brought my attention to CTIX back in January 2015:
http://www.ipharminc.com/press-release/2016/1...g-kevetrin
These quotes were from the company in the middle of a phase 1 dose escalation safety trial. It's easy to understand why some are a bit disappointed to hear three years later that the phase 2a trial ended early, was marked as a success based on p53 modulation, but have no similar sample of efficacy.
As for today's news, I'm disappointed the company still has not received the Prurisol results but it appears to be out of their hands at this time. At least it dispels nasty lies about withholding info due to poor results. I think our deal-making is currently reliant on those results to actually ink anything which is what makes waiting so hard.
And so we march on.
Go IPIX!
Quote:
Why would there be mention of efficacy if it wasn't even part of the trial?
Because the company has done this before. Allow me to share a few snippets from the PR that first brought my attention to CTIX back in January 2015:
http://www.ipharminc.com/press-release/2016/1...g-kevetrin
Quote:
..is pleased to report the near complete disappearance of a metastatic lesion in the spleen of a Stage 4 ovarian cancer patient who was enrolled in the Company’s Phase 1 clinical trial of anti-cancer drug candidate Kevetrin..
Quote:
Subsequent to the second and third Kevetrin cycles, scans showed the spleen lesion to be essentially undetectable and the patient’s disease to be clinically stable.
Quote:
“I can’t overexpress the excitement at Cellceutix regarding Kevetrin or the significance of a metastatic lesion disappearing in a late-stage ovarian cancer patient,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “We don’t know of any other company, regardless of specialization, albeit small molecule, immunotherapy or other, that has published an effect like that in such a hard-to-treat disease like metastatic ovarian cancer during a Phase 1 safety trial. The idea that a stage 4 ovarian cancer patient’s disease was clinically stabilized, although her CA-125 count was increased in the third month, is remarkable.
These quotes were from the company in the middle of a phase 1 dose escalation safety trial. It's easy to understand why some are a bit disappointed to hear three years later that the phase 2a trial ended early, was marked as a success based on p53 modulation, but have no similar sample of efficacy.
As for today's news, I'm disappointed the company still has not received the Prurisol results but it appears to be out of their hands at this time. At least it dispels nasty lies about withholding info due to poor results. I think our deal-making is currently reliant on those results to actually ink anything which is what makes waiting so hard.
And so we march on.
Go IPIX!
(4)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼
